New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
08:39 EDTCPXXCelator Pharmaceuticals initiates PK/PD clinical study of CPX-351
Celator Pharmaceuticals announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics, or PK/PD, study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in adult patients with acute hematologic malignancies, including acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, and myelodysplastic syndrome, or MDS. This study will also include patients with moderate baseline hepatic and renal impairment, extending the range of safety and pharmacokinetic observations to this important group of patients.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
10:20 EDTCPXXCelator participates in lunch meeting with Philadelphia Securities Association
Subscribe for More Information
December 10, 2014
08:33 EDTCPXXCelator Pharmaceuticals' CPX-351 leukemia candidate shows positive results
Subscribe for More Information
December 6, 2014
09:19 EDTCPXXCelator Pharmaceuticals to hold a reception
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use